{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"89","upperLimit":"100","value":"95"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"}],"units":"Participants"}],"description":"One year overall survival estimated using the product-limit method of Kaplan and Meier. Defined as the percentage of patients alive at year one after starting treatment.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive high-dose melphalan IV 200mg/m\\^2 over 30 minutes on days -2 and -1 and undergo autologous peripheral blood stem cell transplantation (Minimum dose of 2 X 10(6) CD34 + cells/kg ) on day 0. Patients receive filgrastim 5ug/kg IV or SQ beginning on day 5 and continuing until blood counts recover. Beginning 4 to 8 weeks after transplantation, patients receive maintenance therapy comprising 1.3 mg/m\\^2 of bortezomib IV on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive 40mg of oral dexamethasone on days 1 to 4. Treatment with dexamethasone repeats every month for 12 months in the absence of disease progression or unacceptable toxicity. Beginning 2 weeks after completion of bortezomib, patients receive 50mg/day of oral thalidomide once daily until disease progression.","id":"OG000","title":"Treatment (Stem Cell Transplant, Maintenance Treatment)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"From date of treatment initiation until death from any cause, assessed up to one year.","title":"One Year Overall Survival","type":"PRIMARY","unitOfMeasure":"percentage of participants"}